Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections
Identifieur interne : 003677 ( Main/Curation ); précédent : 003676; suivant : 003678Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections
Auteurs : Jordan Dubow [États-Unis] ; Angela Kim [États-Unis] ; Jerrold Leikin [États-Unis] ; Kirk Cumpston [États-Unis] ; Sean Bryant [États-Unis] ; Michael Rezak [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-07.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Autonomic Nervous System Diseases (complications), Bontoxilysin, Botulinum Toxins (adverse effects), Dysfunction, Female, Humans, Male, Movement Disorders (drug therapy), Nervous system diseases, Vision Disorders (chemically induced), Visual system, parasympathetic dysfunction, side effects of botulinum toxin B, visual system disturbance.
- MESH :
- chemical , adverse effects : Botulinum Toxins.
- chemically induced : Vision Disorders.
- complications : Autonomic Nervous System Diseases.
- drug therapy : Movement Disorders.
- Adult, Female, Humans, Male.
Abstract
Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20466
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F25
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :002F25
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002083
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003092
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003092
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002F09
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001209
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001209
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001209
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004D60
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E22
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000E99
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001C68
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005146
Links to Exploration step
ISTEX:59E2F4877B7977C1F915CA55E7AB648C4D0EB058Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title>
<author><name sortKey="Dubow, Jordan" sort="Dubow, Jordan" uniqKey="Dubow J" first="Jordan" last="Dubow">Jordan Dubow</name>
</author>
<author><name sortKey="Kim, Angela" sort="Kim, Angela" uniqKey="Kim A" first="Angela" last="Kim">Angela Kim</name>
</author>
<author><name sortKey="Leikin, Jerrold" sort="Leikin, Jerrold" uniqKey="Leikin J" first="Jerrold" last="Leikin">Jerrold Leikin</name>
</author>
<author><name sortKey="Cumpston, Kirk" sort="Cumpston, Kirk" uniqKey="Cumpston K" first="Kirk" last="Cumpston">Kirk Cumpston</name>
</author>
<author><name sortKey="Bryant, Sean" sort="Bryant, Sean" uniqKey="Bryant S" first="Sean" last="Bryant">Sean Bryant</name>
</author>
<author><name sortKey="Rezak, Michael" sort="Rezak, Michael" uniqKey="Rezak M" first="Michael" last="Rezak">Michael Rezak</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:59E2F4877B7977C1F915CA55E7AB648C4D0EB058</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20466</idno>
<idno type="url">https://api.istex.fr/document/59E2F4877B7977C1F915CA55E7AB648C4D0EB058/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002F25</idno>
<idno type="wicri:Area/Istex/Curation">002F25</idno>
<idno type="wicri:Area/Istex/Checkpoint">002083</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dubow J:visual:system:side</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15806568</idno>
<idno type="wicri:Area/PubMed/Corpus">003092</idno>
<idno type="wicri:Area/PubMed/Curation">003092</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F09</idno>
<idno type="wicri:Area/Ncbi/Merge">001209</idno>
<idno type="wicri:Area/Ncbi/Curation">001209</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001209</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dubow J:visual:system:side</idno>
<idno type="wicri:Area/Main/Merge">004D60</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0388373</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E22</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000E99</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C68</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dubow J:visual:system:side</idno>
<idno type="wicri:Area/Main/Merge">005146</idno>
<idno type="wicri:Area/Main/Curation">003677</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title>
<author><name sortKey="Dubow, Jordan" sort="Dubow, Jordan" uniqKey="Dubow J" first="Jordan" last="Dubow">Jordan Dubow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kim, Angela" sort="Kim, Angela" uniqKey="Kim A" first="Angela" last="Kim">Angela Kim</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leikin, Jerrold" sort="Leikin, Jerrold" uniqKey="Leikin J" first="Jerrold" last="Leikin">Jerrold Leikin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cumpston, Kirk" sort="Cumpston, Kirk" uniqKey="Cumpston K" first="Kirk" last="Cumpston">Kirk Cumpston</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center, Albuquerque, New Mexico</wicri:regionArea>
<placeName><region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bryant, Sean" sort="Bryant, Sean" uniqKey="Bryant S" first="Sean" last="Bryant">Sean Bryant</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Emergency Medicine, Cook County Hospital, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rezak, Michael" sort="Rezak, Michael" uniqKey="Rezak M" first="Michael" last="Rezak">Michael Rezak</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-07">2005-07</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="877">877</biblScope>
<biblScope unit="page" to="880">880</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">59E2F4877B7977C1F915CA55E7AB648C4D0EB058</idno>
<idno type="DOI">10.1002/mds.20466</idno>
<idno type="ArticleID">MDS20466</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Autonomic Nervous System Diseases (complications)</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins (adverse effects)</term>
<term>Dysfunction</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Movement Disorders (drug therapy)</term>
<term>Nervous system diseases</term>
<term>Vision Disorders (chemically induced)</term>
<term>Visual system</term>
<term>parasympathetic dysfunction</term>
<term>side effects of botulinum toxin B</term>
<term>visual system disturbance</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Vision Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Autonomic Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Appareil visuel</term>
<term>Bontoxilysin</term>
<term>Système nerveux pathologie</term>
<term>Trouble fonctionnel</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2005:Dubow J:visual:system:side"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title>
<author><name sortKey="Dubow, Jordan" sort="Dubow, Jordan" uniqKey="Dubow J" first="Jordan" last="Dubow">Jordan Dubow</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kim, Angela" sort="Kim, Angela" uniqKey="Kim A" first="Angela" last="Kim">Angela Kim</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leikin, Jerrold" sort="Leikin, Jerrold" uniqKey="Leikin J" first="Jerrold" last="Leikin">Jerrold Leikin</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cumpston, Kirk" sort="Cumpston, Kirk" uniqKey="Cumpston K" first="Kirk" last="Cumpston">Kirk Cumpston</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bryant, Sean" sort="Bryant, Sean" uniqKey="Bryant S" first="Sean" last="Bryant">Sean Bryant</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Emergency Medicine, Cook County Hospital</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rezak, Michael" sort="Rezak, Michael" uniqKey="Rezak M" first="Michael" last="Rezak">Michael Rezak</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0388373</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0388373 INIST</idno>
<idno type="RBID">Pascal:05-0388373</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E22</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000E99</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C68</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dubow J:visual:system:side</idno>
<idno type="wicri:Area/Main/Merge">005146</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title>
<author><name sortKey="Dubow, Jordan" sort="Dubow, Jordan" uniqKey="Dubow J" first="Jordan" last="Dubow">Jordan Dubow</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kim, Angela" sort="Kim, Angela" uniqKey="Kim A" first="Angela" last="Kim">Angela Kim</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leikin, Jerrold" sort="Leikin, Jerrold" uniqKey="Leikin J" first="Jerrold" last="Leikin">Jerrold Leikin</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cumpston, Kirk" sort="Cumpston, Kirk" uniqKey="Cumpston K" first="Kirk" last="Cumpston">Kirk Cumpston</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bryant, Sean" sort="Bryant, Sean" uniqKey="Bryant S" first="Sean" last="Bryant">Sean Bryant</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Emergency Medicine, Cook County Hospital</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rezak, Michael" sort="Rezak, Michael" uniqKey="Rezak M" first="Michael" last="Rezak">Michael Rezak</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term>
<term>Dysfunction</term>
<term>Nervous system diseases</term>
<term>Visual system</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Appareil visuel</term>
<term>Trouble fonctionnel</term>
<term>Bontoxilysin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Botulinum toxin type B (BTX-B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX-A) it has off-label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX-B has also been shown to be a safe and effective alternative for patients who are resistant to BTX-A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX-B use. In this study, we report on three individual patients who received BTX-B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX-B at remote sites.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title>
<author><name sortKey="Dubow, Jordan" sort="Dubow, Jordan" uniqKey="Dubow J" first="Jordan" last="Dubow">Jordan Dubow</name>
</author>
<author><name sortKey="Kim, Angela" sort="Kim, Angela" uniqKey="Kim A" first="Angela" last="Kim">Angela Kim</name>
</author>
<author><name sortKey="Leikin, Jerrold" sort="Leikin, Jerrold" uniqKey="Leikin J" first="Jerrold" last="Leikin">Jerrold Leikin</name>
</author>
<author><name sortKey="Cumpston, Kirk" sort="Cumpston, Kirk" uniqKey="Cumpston K" first="Kirk" last="Cumpston">Kirk Cumpston</name>
</author>
<author><name sortKey="Bryant, Sean" sort="Bryant, Sean" uniqKey="Bryant S" first="Sean" last="Bryant">Sean Bryant</name>
</author>
<author><name sortKey="Rezak, Michael" sort="Rezak, Michael" uniqKey="Rezak M" first="Michael" last="Rezak">Michael Rezak</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:59E2F4877B7977C1F915CA55E7AB648C4D0EB058</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20466</idno>
<idno type="url">https://api.istex.fr/document/59E2F4877B7977C1F915CA55E7AB648C4D0EB058/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002F25</idno>
<idno type="wicri:Area/Istex/Curation">002F25</idno>
<idno type="wicri:Area/Istex/Checkpoint">002083</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dubow J:visual:system:side</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15806568</idno>
<idno type="wicri:Area/PubMed/Corpus">003092</idno>
<idno type="wicri:Area/PubMed/Curation">003092</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F09</idno>
<idno type="wicri:Area/Ncbi/Merge">001209</idno>
<idno type="wicri:Area/Ncbi/Curation">001209</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001209</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dubow J:visual:system:side</idno>
<idno type="wicri:Area/Main/Merge">004D60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections</title>
<author><name sortKey="Dubow, Jordan" sort="Dubow, Jordan" uniqKey="Dubow J" first="Jordan" last="Dubow">Jordan Dubow</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kim, Angela" sort="Kim, Angela" uniqKey="Kim A" first="Angela" last="Kim">Angela Kim</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Plastic Surgery, Section of Ophthalmology, University of Texas, M.D. Anderson Cancer Center, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leikin, Jerrold" sort="Leikin, Jerrold" uniqKey="Leikin J" first="Jerrold" last="Leikin">Jerrold Leikin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Omega, Evanston Northwestern Healthcare, Evanston, and University of Illinois at Chicago and Cook County Hospital, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cumpston, Kirk" sort="Cumpston, Kirk" uniqKey="Cumpston K" first="Kirk" last="Cumpston">Kirk Cumpston</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Emergency Medicine, University of New Mexico and New Mexico Poison Center, Albuquerque, New Mexico</wicri:regionArea>
<placeName><region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bryant, Sean" sort="Bryant, Sean" uniqKey="Bryant S" first="Sean" last="Bryant">Sean Bryant</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Emergency Medicine, Cook County Hospital, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rezak, Michael" sort="Rezak, Michael" uniqKey="Rezak M" first="Michael" last="Rezak">Michael Rezak</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Evanston Northwestern Healthcare and Feinberg School of Medicine, Northwestern University, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-07">2005-07</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="877">877</biblScope>
<biblScope unit="page" to="880">880</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">59E2F4877B7977C1F915CA55E7AB648C4D0EB058</idno>
<idno type="DOI">10.1002/mds.20466</idno>
<idno type="ArticleID">MDS20466</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Autonomic Nervous System Diseases (complications)</term>
<term>Botulinum Toxins (adverse effects)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Movement Disorders (drug therapy)</term>
<term>Vision Disorders (chemically induced)</term>
<term>parasympathetic dysfunction</term>
<term>side effects of botulinum toxin B</term>
<term>visual system disturbance</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Vision Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Autonomic Nervous System Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Botulinum toxin type B (BTX‐B) has been approved by the Food and Drug Administration for the treatment of cervical dystonia. However, as with botulinum toxin type A (BTX‐A) it has off‐label uses, such as for hyperhidrosis, focal dystonias, spasticity, and facial wrinkles. BTX‐B has also been shown to be a safe and effective alternative for patients who are resistant to BTX‐A. The most commonly reported side effects include dry mouth and dysphagia. To date, there have been few reports of visual disturbances associated with BTX‐B use. In this study, we report on three individual patients who received BTX‐B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX‐B at remote sites. © 2005 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003677 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003677 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:59E2F4877B7977C1F915CA55E7AB648C4D0EB058 |texte= Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections }}
This area was generated with Dilib version V0.6.23. |